Jean-Marc Herbert

Since 2016, JM Herbert has been a Venture Partner at GO Capital.

A graduate in engineering and PhD in biochemistry from the University of Clermont-Ferrand (F), JM Herbert did his PhD in cell biology and biochemistry at the Clinical Research Center in London (UK). JM Herbert has over 35 years’ industrial experience in pharmaceutical R&D. He held the position of International Director of the Cardiovascular/Thrombosis Research Department at Sanofi Recherche and played a major role in the discovery, development and marketing of Plavix® and Arixtra®. In 2001-09, he was Deputy and then Director of Discovery for Sanofi worldwide.

JM Herbert was co-founder and Chairman of AV-Care in Brest (France), a company spun off from S. Timsit’s work at the University of Brittany, merged in 2020 with Acticor Biotech, developing a product for the treatment of thrombotic stroke.

JM Herbert is Chairman of Arkely-Consulting, a translational research consultancy for the discovery and development of innovative drugs, and since 2022, Chairman of Abcely, a biotech company developing an innovative treatment for mucosal cancers (esophageal, gastric, colorectal, etc.).

JM Herbert is a member of the strategic advisory boards of several biotech companies in fields such as oncology, gene and cell therapy, infectious and orphan diseases.

JM Herbert is a member of several international scientific societies and the editorial and review boards of several leading peer-reviewed scientific journals. He is the author of over 400 articles and is listed as inventor on more than 50 patents in various fields, including thrombosis, vascular biology, inflammation, cardiology and cancer.